$NGNE
Neurogene Inc.

2021 Q4 Form 10-Q Financial Statement

#000162828021021773 Filed on November 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.414M $5.556M $5.300M
YoY Change 11.63% 43.94% 7.51%
% of Gross Profit
Research & Development $9.760M $9.896M $9.824M
YoY Change 25.29% 59.2% 102.85%
% of Gross Profit
Depreciation & Amortization $390.0K $356.0K $310.0K
YoY Change 85.71% 87.37% 40.91%
% of Gross Profit
Operating Expenses $15.17M $9.896M $9.824M
YoY Change 20.05% 59.2% 0.56%
Operating Profit -$15.45M -$15.12M
YoY Change 586.76% 54.82%
Interest Expense $7.000K $6.000K $6.000K
YoY Change -40.0% -85.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $6.000K -$5.000K
YoY Change 500.0% -121.74%
Pretax Income -$15.17M -$15.45M -$15.13M
YoY Change 19.99% 586.49% 55.17%
Income Tax
% Of Pretax Income
Net Earnings -$15.17M -$15.45M -$15.13M
YoY Change 19.99% 586.79% 55.23%
Net Earnings / Revenue
Basic Earnings Per Share -$0.28 -$0.27
Diluted Earnings Per Share -$275.2K -$0.28 -$0.27
COMMON SHARES
Basic Shares Outstanding 42.43M shares 55.09M shares 55.03M shares
Diluted Shares Outstanding 55.09M shares 55.03M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $142.5M $154.9M $164.2M
YoY Change -26.03% -23.0% 26.72%
Cash & Equivalents $142.5M $154.9M $164.2M
Short-Term Investments $0.00
Other Short-Term Assets $1.522M $1.574M $3.261M
YoY Change -22.58% 132.76%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $144.0M $156.5M $167.5M
YoY Change -25.98% -24.25% 27.86%
LONG-TERM ASSETS
Property, Plant & Equipment $6.452M $6.257M $6.113M
YoY Change 80.73% -54.33% 97.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.928M $1.988M $1.932M
YoY Change 0.1% 98.8% 70.52%
Total Long-Term Assets $19.27M $19.44M $19.53M
YoY Change 20.49% 28.72% 36.3%
TOTAL ASSETS
Total Short-Term Assets $144.0M $156.5M $167.5M
Total Long-Term Assets $19.27M $19.44M $19.53M
Total Assets $163.3M $175.9M $187.0M
YoY Change -22.45% -20.64% 28.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.415M $7.774M $6.407M
YoY Change 2.99% -18.17% 6.78%
Accrued Expenses $1.166M $1.118M $1.073M
YoY Change 66.57% 272.67% 436.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $55.00K $104.0K $104.0K
YoY Change 4.0%
Total Short-Term Liabilities $8.636M $8.996M $7.584M
YoY Change 9.47% -9.13% 20.38%
LONG-TERM LIABILITIES
Long-Term Debt $67.00K $68.00K $68.00K
YoY Change -33.0% -32.0% -32.0%
Other Long-Term Liabilities $11.70M $12.00M $12.30M
YoY Change 3.5% 5.3% 20.59%
Total Long-Term Liabilities $11.76M $12.07M $12.37M
YoY Change 3.18% 4.97% 20.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.636M $8.996M $7.584M
Total Long-Term Liabilities $11.76M $12.07M $12.37M
Total Liabilities $20.40M $21.07M $19.95M
YoY Change 5.68% -1.55% 20.19%
SHAREHOLDERS EQUITY
Retained Earnings -$393.5M -$378.3M -$362.9M
YoY Change 18.24% 14.14%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $142.9M $154.9M $167.1M
YoY Change
Total Liabilities & Shareholders Equity $163.3M $175.9M $187.0M
YoY Change -22.45% -20.64% 28.69%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021 Q2
OPERATING ACTIVITIES
Net Income -$15.17M -$15.45M -$15.13M
YoY Change 19.99% 586.79% 55.23%
Depreciation, Depletion And Amortization $390.0K $356.0K $310.0K
YoY Change 85.71% 87.37% 40.91%
Cash From Operating Activities -$12.17M -$8.756M -$13.27M
YoY Change 31.83% 7196.67% 51.01%
INVESTING ACTIVITIES
Capital Expenditures -$396.0K -$587.0K -$1.190M
YoY Change -39.08% 19.8% 22.68%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$396.0K -$587.0K -$1.190M
YoY Change -39.08% 19.8% 22.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 107.0K 32.00K 313.0K
YoY Change -91.71% -99.96% 4.33%
NET CHANGE
Cash From Operating Activities -12.17M -8.756M -13.27M
Cash From Investing Activities -396.0K -587.0K -1.190M
Cash From Financing Activities 107.0K 32.00K 313.0K
Net Change In Cash -12.46M -9.311M -14.15M
YoY Change 45.02% -113.01% 49.59%
FREE CASH FLOW
Cash From Operating Activities -$12.17M -$8.756M -$13.27M
Capital Expenditures -$396.0K -$587.0K -$1.190M
Free Cash Flow -$11.77M -$8.169M -$12.08M
YoY Change 37.2% -2307.84% 54.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001404644
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36327
dei Entity Registrant Name
EntityRegistrantName
Neoleukin Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0542593
dei Entity Address Address Line1
EntityAddressAddressLine1
188 East Blaine Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 450
dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98102
dei City Area Code
CityAreaCode
866
dei Local Phone Number
LocalPhoneNumber
245-0312
dei Security12b Title
Security12bTitle
Common Stock, par value $0.000001
dei Trading Symbol
TradingSymbol
NLTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42428134 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
154924000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192556000 USD
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1574000 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1966000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
156498000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
194522000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6257000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3570000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11008000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10154000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
183000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
347000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1988000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1926000 USD
CY2021Q3 us-gaap Assets
Assets
175934000 USD
CY2020Q4 us-gaap Assets
Assets
210519000 USD
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7774000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7181000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1118000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
659000 USD
CY2021Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
104000 USD
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
49000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8996000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7889000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12004000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11306000 USD
CY2021Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
68000 USD
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
108000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
21068000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
19303000 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42196296 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42428134 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42428134 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42196296 shares
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
533197000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
524022000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-378331000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-332806000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
154866000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
191216000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
175934000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
210519000 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9896000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6216000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29402000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16557000 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5556000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3860000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5125000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16122000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12359000 USD
CY2021Q3 us-gaap Gain Or Loss On Sale Of Stock In Subsidiary
GainOrLossOnSaleOfStockInSubsidiary
0 USD
CY2020Q3 us-gaap Gain Or Loss On Sale Of Stock In Subsidiary
GainOrLossOnSaleOfStockInSubsidiary
7826000 USD
us-gaap Gain Or Loss On Sale Of Stock In Subsidiary
GainOrLossOnSaleOfStockInSubsidiary
0 USD
us-gaap Gain Or Loss On Sale Of Stock In Subsidiary
GainOrLossOnSaleOfStockInSubsidiary
7826000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15452000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2250000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-45524000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-21090000 USD
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
453000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-15446000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2249000 USD
us-gaap Net Income Loss
NetIncomeLoss
-45525000 USD
us-gaap Net Income Loss
NetIncomeLoss
-20637000 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55087777 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55087777 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54121676 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54121676 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55020059 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55020059 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50896014 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50896014 shares
us-gaap Net Income Loss
NetIncomeLoss
-45525000 USD
us-gaap Net Income Loss
NetIncomeLoss
-20637000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
8548000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3393000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
916000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
578000 USD
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
730000 USD
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
784000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-180000 USD
nltx Write Off Of Right Of Use Asset Upon Lease Termination
WriteOffOfRightOfUseAssetUponLeaseTermination
0 USD
nltx Write Off Of Right Of Use Asset Upon Lease Termination
WriteOffOfRightOfUseAssetUponLeaseTermination
113000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-36000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
5026000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
332000 USD
nltx Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
0 USD
nltx Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
169000 USD
nltx Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-427000 USD
nltx Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
313000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35390000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15346000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2867000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1566000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2867000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1566000 USD
nltx Commission Fees For Issuance Of Common Stock And Pre Funded Warrants
CommissionFeesForIssuanceOfCommonStockAndPreFundedWarrants
4600000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
71675000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
355000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
408000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
625000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75847000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-37632000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4576000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
219000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
0 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
49000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
58935000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
193434000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143093000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
155802000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
202028000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1584000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
10618000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
297000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
271000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
191216000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
282000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2420000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-14950000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
178968000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
95000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
219000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2918000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-15129000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
167071000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
31000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3210000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-15446000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
154866000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
141687000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3392000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
683000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-8642000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
137120000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
303000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1022000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-9746000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
128699000 USD
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
71320000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
882000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1688000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2249000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
200340000 USD
us-gaap Nature Of Operations
NatureOfOperations
Nature of operationsNeoleukin Therapeutics, Inc. (“Neoleukin” or “the Company”) is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.
us-gaap Use Of Estimates
UseOfEstimates
Use of estimates and assumptionsThe preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring estimates include valuation and recognition of stock-based compensation, the incremental borrowing rate utilized in the measurement of operating and finance lease liabilities, amortization and depreciation of property, plant and equipment and intangible assets, and pre-clinical, clinical, and other accruals. Actual results could differ from those estimates.
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Security Deposit
SecurityDeposit
900000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
154924000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192556000 USD
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
878000 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
878000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
155802000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
193434000 USD
nltx Tenant Improvement Allowance
TenantImprovementAllowance
9500000 USD
CY2020Q2 nltx Termination Fees For Lease Termination
TerminationFeesForLeaseTermination
500000 USD
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
-300000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-200000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11000000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10200000 USD
CY2021Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
200000 USD
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
300000 USD
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42428134 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42428134 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42196296 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42196296 shares
nltx Class Of Warrant Or Right Notice Period
ClassOfWarrantOrRightNoticePeriod
P61D
nltx Percentage Of Outstanding Stock Per Stockholder Maximum
PercentageOfOutstandingStockPerStockholderMaximum
0.0999
CY2020Q3 nltx Underwriting Discounts Commission Fees And Offering Costs For Issuance Of Common Stock And Pre Funded Warrants
UnderwritingDiscountsCommissionFeesAndOfferingCostsForIssuanceOfCommonStockAndPreFundedWarrants
4900000 USD
CY2020Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
71300000 USD
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3210000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1688000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8548000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3393000 USD
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
35900000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y11M19D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0034
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8917
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9484
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8918
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9386
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y25D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y25D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y10D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y7D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0083
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3019749 shares
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M15D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
53127000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0089
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0042
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6846289 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.42
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.85
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
124366 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.28
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
122534 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.14
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9619138 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.16
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M10D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
18377000 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3134157 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.90
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M29D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
9339000 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
124366 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1300000 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
581270 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2800000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.69
CY2021Q3 nltx Number Of Common Stock Shares Issued Upon Vesting Of Restricted Stock Unit
NumberOfCommonStockSharesIssuedUponVestingOfRestrictedStockUnit
1 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9814603 shares
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6972441 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9814603 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6972441 shares

Files In Submission

Name View Source Status
0001628280-21-021773-index-headers.html Edgar Link pending
0001628280-21-021773-index.html Edgar Link pending
0001628280-21-021773.txt Edgar Link pending
0001628280-21-021773-xbrl.zip Edgar Link pending
exhibit3112021q3.htm Edgar Link pending
exhibit3122021q3.htm Edgar Link pending
exhibit3212021q3.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nltx-20210930.htm Edgar Link pending
nltx-20210930.xsd Edgar Link pending
nltx-20210930_cal.xml Edgar Link unprocessable
nltx-20210930_def.xml Edgar Link unprocessable
nltx-20210930_htm.xml Edgar Link completed
nltx-20210930_lab.xml Edgar Link unprocessable
nltx-20210930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending